从Brolucizumab切换到Faricimab：一项TRUCKEE研究分析：从Brolucizumab切换到Faricimab：一项TRUCKEE研究分析。

IF 4.2 1区医学 Q1 OPHTHALMOLOGY

American Journal of Ophthalmology Pub Date : 2025-08-13 DOI:10.1016/j.ajo.2025.08.018

CEREN SOYLU , GIULIA CORRADETTI , MAI ALHELALY , HANNAH KHAN , AAMIR A. AZIZ , HUMA KHAN , HAAZIQ ALI , HUMZA SULAHRIA , ARSHAD M. KHANANI , SRINIVAS SADDA

{"title":"从Brolucizumab切换到Faricimab：一项TRUCKEE研究分析：从Brolucizumab切换到Faricimab：一项TRUCKEE研究分析。","authors":"CEREN SOYLU , GIULIA CORRADETTI , MAI ALHELALY , HANNAH KHAN , AAMIR A. AZIZ , HUMA KHAN , HAAZIQ ALI , HUMZA SULAHRIA , ARSHAD M. KHANANI , SRINIVAS SADDA","doi":"10.1016/j.ajo.2025.08.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To investigate anatomical and functional outcomes in a subset of eyes with neovascular age-related macular degeneration (nAMD) switched from brolucizumab to faricimab in the real-world TRUCKEE study.</div></div><div><h3>Design</h3><div>Retrospective, multicentric clinical cohort study.</div></div><div><h3>Subjects and Participants</h3><div>134 eyes of 108 patients were switched from brolucizumab to faricimab. This study included 56 eyes (49 patients) with complete data after 1 injection of faricimab and 40 eyes (34 patients) with complete data after 3 injections of faricimab.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective chart review was conducted on real-world participants enrolled in the TRUCKEE study switched from brolucizumab to faricimab for the treatment of nAMD. Participants were considered eligible for this post-hoc analysis if they had documented anatomical and functional outcome data following 1 and 3 injections of faricimab after being switched from brolucizumab. A comparative analysis was performed using the Wilcoxon signed-rank test.</div></div><div><h3>Main Outcome Measures</h3><div>Change in best corrected visual acuity (BCVA) measured in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, durability – defined as time interval between treatments in days, and central subfield thickness (CST), following 1 and 3 injections of faricimab.</div></div><div><h3>Results</h3><div>The mean age of patients who had complete data after 1 injection of faricimab was 81.1 ± 7.1 years, and 25 were males. After 1 injection of faricimab following the switch, (mean treatment interval of 57.0 ± 32.9 days) a significant reduction in CST was observed (mean -5.25 µm, <em>P = .</em>048). Changes in BCVA and durability were not statistically significant after 1 injection. The mean age of patients who had data after 3 injections was 80.4±7.7 years, and 16 were males. The mean CST reduction measured -11.28 µm, when comparing post-faricimab with post-brolucizumab values (<em>P = .</em>086). Additionally, after 3 injections of faricimab, a numerical increase in retreatment interval (+5.0 days, <em>P = .</em>769) and improvement in visual acuity (BCVA +1.63 letters, <em>P = .</em>174) were observed, though these were not statistically significant.</div></div><div><h3>Conclusions</h3><div>Switching from brolucizumab to faricimab was associated with numerical improvements in BCVA, CST, and retreatment interval. The apparent benefit in patients already on maximum VEGF suppression with brolucizumab, may suggest the relevance of angiopoetin-2 suppression with faricimab.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"280 ","pages":"Pages 169-175"},"PeriodicalIF":4.2000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis\",\"authors\":\"CEREN SOYLU , GIULIA CORRADETTI , MAI ALHELALY , HANNAH KHAN , AAMIR A. AZIZ , HUMA KHAN , HAAZIQ ALI , HUMZA SULAHRIA , ARSHAD M. KHANANI , SRINIVAS SADDA\",\"doi\":\"10.1016/j.ajo.2025.08.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To investigate anatomical and functional outcomes in a subset of eyes with neovascular age-related macular degeneration (nAMD) switched from brolucizumab to faricimab in the real-world TRUCKEE study.</div></div><div><h3>Design</h3><div>Retrospective, multicentric clinical cohort study.</div></div><div><h3>Subjects and Participants</h3><div>134 eyes of 108 patients were switched from brolucizumab to faricimab. This study included 56 eyes (49 patients) with complete data after 1 injection of faricimab and 40 eyes (34 patients) with complete data after 3 injections of faricimab.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective chart review was conducted on real-world participants enrolled in the TRUCKEE study switched from brolucizumab to faricimab for the treatment of nAMD. Participants were considered eligible for this post-hoc analysis if they had documented anatomical and functional outcome data following 1 and 3 injections of faricimab after being switched from brolucizumab. A comparative analysis was performed using the Wilcoxon signed-rank test.</div></div><div><h3>Main Outcome Measures</h3><div>Change in best corrected visual acuity (BCVA) measured in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, durability – defined as time interval between treatments in days, and central subfield thickness (CST), following 1 and 3 injections of faricimab.</div></div><div><h3>Results</h3><div>The mean age of patients who had complete data after 1 injection of faricimab was 81.1 ± 7.1 years, and 25 were males. After 1 injection of faricimab following the switch, (mean treatment interval of 57.0 ± 32.9 days) a significant reduction in CST was observed (mean -5.25 µm, <em>P = .</em>048). Changes in BCVA and durability were not statistically significant after 1 injection. The mean age of patients who had data after 3 injections was 80.4±7.7 years, and 16 were males. The mean CST reduction measured -11.28 µm, when comparing post-faricimab with post-brolucizumab values (<em>P = .</em>086). Additionally, after 3 injections of faricimab, a numerical increase in retreatment interval (+5.0 days, <em>P = .</em>769) and improvement in visual acuity (BCVA +1.63 letters, <em>P = .</em>174) were observed, though these were not statistically significant.</div></div><div><h3>Conclusions</h3><div>Switching from brolucizumab to faricimab was associated with numerical improvements in BCVA, CST, and retreatment interval. The apparent benefit in patients already on maximum VEGF suppression with brolucizumab, may suggest the relevance of angiopoetin-2 suppression with faricimab.</div></div>\",\"PeriodicalId\":7568,\"journal\":{\"name\":\"American Journal of Ophthalmology\",\"volume\":\"280 \",\"pages\":\"Pages 169-175\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002939425004222\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002939425004222","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：在TRUCKEE研究中，研究从brolucizumab切换到faricimab的新生血管性年龄相关性黄斑变性（nAMD）患者的解剖和功能结果。设计：回顾性、多中心临床队列研究。108名患者的134只眼睛从brolucizumab切换到faricimab。本研究纳入56只眼（49例），1次注射法利西单抗后资料完整；40只眼（34例），3次注射法利西单抗后资料完整。方法对TRUCKEE研究中从brolucizumab转为faricimab治疗nAMD的真实参与者进行多中心回顾性图表回顾。如果参与者在从brolucizumab切换到faricimab后有记录的1和3次注射法利西单抗后的解剖和功能结果数据，则认为他们有资格进行这项事后分析。采用Wilcoxon符号秩检验进行比较分析。主要观察指标：1次和3次注射法利昔单抗后，糖尿病视网膜病变早期治疗研究（ETDRS）字母中测量的最佳矫正视力（BCVA）的变化，持久性（定义为治疗间隔时间，以天为单位）和中心亚野厚度（CST）。结果1次注射法昔单抗后资料完整的患者平均年龄为81.1±7.1岁，男性25例。转换后注射1次法利昔单抗后（平均治疗间隔为57.0±32.9天），CST显著降低（平均-5.25µm, P = 0.048）。1次注射后BCVA和耐久性变化无统计学意义。3次注射后有资料的患者平均年龄为80.4±7.7岁，男性16例。当比较faricimab后与brolucizumab后的值时，平均CST降低值为-11.28µm （P = 0.086）。此外，法利昔单抗3次注射后，复诊间隔增加（+5.0天，P = 0.769），视力改善（BCVA +1.63字母，P = 0.174），但无统计学意义。从brolucizumab切换到faricimab与BCVA、CST和再治疗间隔的数值改善相关。在已经使用brolucizumab最大限度抑制VEGF的患者中，明显的获益可能表明血管生成素-2抑制与faricimab相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis

Objective

To investigate anatomical and functional outcomes in a subset of eyes with neovascular age-related macular degeneration (nAMD) switched from brolucizumab to faricimab in the real-world TRUCKEE study.

Design

Retrospective, multicentric clinical cohort study.

Subjects and Participants

134 eyes of 108 patients were switched from brolucizumab to faricimab. This study included 56 eyes (49 patients) with complete data after 1 injection of faricimab and 40 eyes (34 patients) with complete data after 3 injections of faricimab.

Methods

A multicenter, retrospective chart review was conducted on real-world participants enrolled in the TRUCKEE study switched from brolucizumab to faricimab for the treatment of nAMD. Participants were considered eligible for this post-hoc analysis if they had documented anatomical and functional outcome data following 1 and 3 injections of faricimab after being switched from brolucizumab. A comparative analysis was performed using the Wilcoxon signed-rank test.

Main Outcome Measures

Change in best corrected visual acuity (BCVA) measured in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, durability – defined as time interval between treatments in days, and central subfield thickness (CST), following 1 and 3 injections of faricimab.

Results

The mean age of patients who had complete data after 1 injection of faricimab was 81.1 ± 7.1 years, and 25 were males. After 1 injection of faricimab following the switch, (mean treatment interval of 57.0 ± 32.9 days) a significant reduction in CST was observed (mean -5.25 µm, P = .048). Changes in BCVA and durability were not statistically significant after 1 injection. The mean age of patients who had data after 3 injections was 80.4±7.7 years, and 16 were males. The mean CST reduction measured -11.28 µm, when comparing post-faricimab with post-brolucizumab values (P = .086). Additionally, after 3 injections of faricimab, a numerical increase in retreatment interval (+5.0 days, P = .769) and improvement in visual acuity (BCVA +1.63 letters, P = .174) were observed, though these were not statistically significant.

Conclusions

Switching from brolucizumab to faricimab was associated with numerical improvements in BCVA, CST, and retreatment interval. The apparent benefit in patients already on maximum VEGF suppression with brolucizumab, may suggest the relevance of angiopoetin-2 suppression with faricimab.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Ophthalmology 医学-眼科学

CiteScore

9.20

自引率

7.10%

发文量

406

审稿时长

36 days

期刊介绍： The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect. The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports. Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.